secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001193125-22-264928
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179
------------------------------------------------------------------------

- Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.
- Zymergen stockholders received 0.9179 Ginkgo Class A shares per Zymergen share held.
- Zymergen shares will cease trading on Nasdaq; Ginkgo common stock continues on NYSE as DNA.
- Expected to enhance Ginkgo's platform with added automation, software, and biological engineering expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/0001193125-22-264928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/d413226d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-264928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer